KR20230123474A - 안정화된 tcr 작제물 및 사용 방법 - Google Patents

안정화된 tcr 작제물 및 사용 방법 Download PDF

Info

Publication number
KR20230123474A
KR20230123474A KR1020237020556A KR20237020556A KR20230123474A KR 20230123474 A KR20230123474 A KR 20230123474A KR 1020237020556 A KR1020237020556 A KR 1020237020556A KR 20237020556 A KR20237020556 A KR 20237020556A KR 20230123474 A KR20230123474 A KR 20230123474A
Authority
KR
South Korea
Prior art keywords
tcr
trac
amino acid
trbc
disulfide bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237020556A
Other languages
English (en)
Korean (ko)
Inventor
에릭 에스코바르-카브레라
리 프리버거
다니엘 티. 패튼
레너드 지. 프레스타
패트릭 파버
찰스 마이클 스티븐스
Original Assignee
자임워크스 비씨 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 자임워크스 비씨 인코포레이티드 filed Critical 자임워크스 비씨 인코포레이티드
Publication of KR20230123474A publication Critical patent/KR20230123474A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237020556A 2020-12-21 2021-12-21 안정화된 tcr 작제물 및 사용 방법 Pending KR20230123474A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063128601P 2020-12-21 2020-12-21
US63/128,601 2020-12-21
PCT/CA2021/051855 WO2022133592A1 (en) 2020-12-21 2021-12-21 Stabilized tcr constructs and methods of use

Publications (1)

Publication Number Publication Date
KR20230123474A true KR20230123474A (ko) 2023-08-23

Family

ID=82157307

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237020556A Pending KR20230123474A (ko) 2020-12-21 2021-12-21 안정화된 tcr 작제물 및 사용 방법

Country Status (8)

Country Link
US (1) US20240409604A9 (https=)
EP (1) EP4263593A4 (https=)
JP (1) JP2023554119A (https=)
KR (1) KR20230123474A (https=)
CN (1) CN116648256A (https=)
AU (1) AU2021408160A1 (https=)
CA (1) CA3167637A1 (https=)
WO (1) WO2022133592A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202000025SA (en) 2017-07-14 2020-02-27 Immatics Biotechnologies Gmbh Improved dual specificity polypeptide molecule
EP4334361A1 (en) 2021-05-05 2024-03-13 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding prame
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
WO2025140554A1 (en) * 2023-12-29 2025-07-03 Shanghai Epimab Biotherapeutics Co., Ltd. Fusion proteins and uses thereof
CN118108833B (zh) * 2024-03-12 2025-05-02 缇纱(合肥)生物技术有限公司 引入外源二硫键的tcr恒定区及其产品和应用
WO2025214470A1 (zh) * 2024-04-12 2025-10-16 江苏恒瑞医药股份有限公司 包含t细胞受体恒定区的蛋白质及其医药用途
WO2025224084A1 (en) 2024-04-22 2025-10-30 Engimmune Therapeutics Ag Proteins comprising t cell receptor constant domains

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110139873A (zh) * 2016-10-03 2019-08-16 朱诺治疗学股份有限公司 Hpv特异性结合分子
CN117843810A (zh) * 2017-09-22 2024-04-09 上海药明生物技术有限公司 新型双特异性多肽复合物
AU2018337142B2 (en) * 2017-09-22 2025-07-03 Wuxi Biologics Ireland Limited. Novel bispecific CD3/CD19 polypeptide complexes
BR112020006643A2 (pt) * 2017-10-03 2020-09-24 Juno Therapeutics Inc moléculas de ligação específica ao hpv
KR20210020873A (ko) * 2018-04-05 2021-02-24 주노 쎄러퓨티크스 인코퍼레이티드 재조합 수용체를 발현하는 τ 세포, 관련 폴리뉴클레오티드 및 방법
AU2019249209A1 (en) * 2018-04-05 2020-10-15 Juno Therapeutics, Inc. T cell receptors and engineered cells expressing same

Also Published As

Publication number Publication date
US20240052009A1 (en) 2024-02-15
CA3167637A1 (en) 2022-06-30
JP2023554119A (ja) 2023-12-26
WO2022133592A1 (en) 2022-06-30
AU2021408160A1 (en) 2023-06-29
EP4263593A1 (en) 2023-10-25
US20240409604A9 (en) 2024-12-12
EP4263593A4 (en) 2025-05-07
CN116648256A (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
US12559555B2 (en) Anti-LILRB4 antibodies and derivative products
US20240052009A1 (en) Stabilized tcr constructs and methods of use
JP7410143B2 (ja) 二重特異性抗体及びその用途
US11851466B2 (en) Targeted IL-12 heterodimeric Fc-fusion proteins
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
JP7847584B2 (ja) 免疫細胞機能をモジュレートするためのｃｄ８抗原結合分子を有する融合物
KR102562519B1 (ko) IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질
EP3180361B1 (en) Recombinant antibody molecule and its use for target cell restricted t cell activation
JP6441079B2 (ja) 二重特異性抗体分子
WO2021202678A1 (en) Masked il-12 cytokines and their cleavage products
CA3131016A1 (en) Multifunctional molecules that bind to calreticulin and uses thereof
US20220010015A1 (en) Antibodies binding to cd3
JP2025542327A (ja) 新規抗ｇｐｒｃ５ｄ抗体
KR20230051615A (ko) Siglec-3/cd33을 결합시키기 위한 물질 및 방법
US20250243275A1 (en) Multi-domain binding molecules
KR20240111783A (ko) 면역 반응을 위한 강화된 다중특이성 결합제를 포함하는 조성물
HK40099262A (zh) 稳定化的tcr构建体及使用方法
CN116113434A (zh) 对Fc γ RIIB具有选择性的异二聚体Fc变体
KR20260042160A (ko) 이중특이적 폴리펩티드 분자
KR20250067799A (ko) 항-flag 항체
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物
CN118284625A (zh) 抗tyrp1/抗cd3双特异性抗体与tyrp1特异性抗体的组合疗法
EA047121B1 (ru) Материалы и способы для связывания siglec-3/cd33
HK40092773A (zh) 对FC γ RIIB具有选择性的异二聚体FC变体
TW201249866A (en) Antigen binding proteins

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230619

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20241220

Comment text: Request for Examination of Application